scholarly journals Reply to the Letter “Comment on Regarding Manuscript ‘Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies’”

Liver Cancer ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 163-163
Author(s):  
Kazuhiro Nouso ◽  
Kazuya Kariyama
Keyword(s):  
Hepatocellular Carcinoma ◽  
Intermediate Stage ◽  
Letter Comment

Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?

Radiology ◽  
2021 ◽  
Vol 298 (3) ◽  
pp. 680-692
Author(s):  
Shuling Chen ◽  
Zhenwei Peng ◽  
Yaojun Zhang ◽  
Minshan Chen ◽  
Jiaping Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Intermediate Stage

scholarly journals Management of patients with intermediate stage hepatocellular carcinoma

2020 ◽  
Vol 12 ◽  
pp. 175883592097084
Author(s):  
David Prince ◽  
Ken Liu ◽  
Weiqi Xu ◽  
Minjiang Chen ◽  
Jin-Yu Sun ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Standard Of Care ◽  
Intermediate Stage ◽  
Tumor Burden ◽  
Current Standard ◽  
Current Management ◽  
Heterogenous Group ◽  
Patient Subgroups ◽  
Significant Health ◽  
Systemic Therapies

Hepatocellular carcinoma (HCC) causes a significant health burden globally and its impact is expected to increase in the coming years. Intermediate stage HCC, as defined by the Barcelona Clinic Liver Cancer (BCLC) system stage B, represents up to 30% of patients at diagnosis and encompasses a broad spectrum of tumor burden. Several attempts have been made to further subclassify this heterogenous group. The current standard of care recommended by BCLC for intermediate stage HCC patients is transarterial chemoembolization (TACE), with modest outcomes reported. While refinements have been made to TACE technique and patient selection, it remains non-curative. In the real-world setting, only 60% of patients with intermediate stage HCC receive TACE, with the remainder deviating to a range of other therapies that have shown promise in select patient subgroups. These include curative treatments (resection, ablation, and liver transplantation), radiotherapy (stereotactic and radioembolization), systemic therapies, and their combination. In this review, we summarize the classifications and current management for patients with intermediate stage HCC as well as highlight recent key developments in this space.

Application of BCLC-B subclassification and Hong Kong Liver Cancer Systems to intermediate stage hepatocellular carcinoma

2020 ◽  
Vol 52 ◽  
pp. e54
Author(s):  
G. Ricco ◽  
C.O. Demirtas ◽  
F. Oliveri ◽  
P. Colombatto ◽  
O.C. Ozdogan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hong Kong ◽  
Liver Cancer ◽  
Intermediate Stage
Sign in / Sign up

Export Citation Format

Share Document